Previous Close | 130.23 |
Open | 130.82 |
Bid | 130.45 x 800 |
Ask | 130.46 x 800 |
Day's Range | 130.10 - 130.88 |
52 Week Range | 99.14 - 133.10 |
Volume | |
Avg. Volume | 8,207,993 |
Market Cap | 330.491B |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | 144.98 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (2.37%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
Surpasses its goal of reaching 25 million women by 2025 RAHWAY, NJ / ACCESSWIRE / May 8, 2024 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company's global maternal health initiative, ...